A Phase Ib Multicentre Study of AZD5363 Monotherapy to Assess Anti-Tumour Activity, Safety, Tolerability, and Pharmacokinetics in Patients With Metastatic Castrate-Resistant Prostate Cancer (mCRPC) (PYRUS)
A Phase Ib Multicentre Study of AZD5363 Monotherapy to Assess Anti-Tumour Activity, Safety,
Tolerability, and Pharmacokinetics in Patients With Metastatic Castrate-Resistant Prostate
Cancer (mCRPC) (PYRUS)
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening
Parts A and B: Anti-tumour activity by measurement of changes in circulating prostate-specific antigen (PSA)
PSA measured from beasline for every 4 weeks. Primary assesment is at 12 weeks
No
Paul Stockman, MBCHB, PHD
Study Director
AstraZeneca
United Kingdom: Medicines and Healthcare Products Regulatory Agency
D3610C00003
NCT01692262
October 2012
August 2014
Name | Location |
---|---|
Research Site | Battle Kreek, Michigan |
Research Site | Belleville, New Jersey |
Reserach Site | Sarasota, Florida |
Reserach Site | Boston, Massachusetts |
Reserach Site | Nashville, Tennessee |